Navigation Links
Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
Date:12/4/2013

BUFFALO, N.Y., Dec. 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals announced today that they have received Orphan Drug designation for KX02 for the treatment of gliomas, which are the most common and aggressive form of brain cancer.  Orphan drug status qualifies Kinex for seven years of exclusivity after formal marketing approval, as well as further development incentives. KX02, a dual src/pre-tubulin inhibitor, is a small molecule drug that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including those that are resistant to Temozolomide (T98G), the most widely used chemotherapy for the treatment of malignant glioma.  In a well-established brain tumor animal model, KX02 consistently clears brain tumors after 4 weeks of therapy, in 30-60% of treated animals. These studies showed that KX02 induced more necrosis compared to Temodar, and also generated an immune response to the glioblastoma tumor cells. Pharmacokinetic studies showed that KX02 is absorbed orally and has 76% penetration into brain tissue from plasma. 

Dr. David Hangauer, Chief Scientific Officer of Kinex stated, "Receiving Orphan Drug Status for KX02 speaks to the need for new treatment options for patients with gliomas. KX02 is a novel compound with good potential for these patients in terms of generating a durable immune response to tumor cells in mice that allow the animals to live to their full life expectancy without tumor recurrence or further drug treatment.  We are looking forward to moving this novel compound into the clinic."

"This is an important regulatory milestone for Kinex," stated Dr. Lyn Dyster, Senior VP of Operations at Kinex.  "The orphan drug designation will facilitate our goal of developing KX02 as a potentially new and effective treatment for patients with gliomas. The standard treatment for glioblastoma cons
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
2. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
3. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
4. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
5. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
6. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
7. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
8. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
9. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
10. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
11. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... NASHVILLE, Tenn. , Aug. 19, 2014 /PRNewswire/ ... to provide its patient experience technology to ... Health. Under the five-year agreement, CarePoint Health will ... of Bayonne Medical Center, Christ Hospital and Hoboken ... platform offers a range of software solutions to ...
(Date:8/19/2014)... BIRMINGHAM, Ala. , Aug. 19, 2014  The Alabama ... re-affirmed that patients can sue drug makers who mislead doctors ... cause harmful side‑effects.  The case is Weeks v. Wyeth, and ... drug makers in that same case last year. Heninger Garrison ... represent the patient in the case, Danny Weeks ...
(Date:8/19/2014)... , Aug. 19, 2014 Talyst, a ... be exhibiting at the 2014 NPPA Summer Conference in ... will be showcasing its 340B software products and services. ... 340B splitting solutions, supplying over 400 customers with a ... of 340B solutions including its latest solution, AutoSplit® Contract ...
Breaking Medicine Technology:Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Talyst Exhibits at the NPPA Summer Conference 2
... 24 NacTel (North Atlantic Communications), a leading ... successfully installed and integrated a new state-of-the-art customer ... one of the fastest growing durable medical equipment ... sophisticated feature set to serve its customers, and ...
... Inc. and Cedarlane today announced that they have entered ... distribute high value reagent proteins produced by Pfenex to ... products initially distributed will be vaccine carrier proteins such ... related growth factors including G-CSF and Interferon beta 1-b. ...
Cached Medicine Technology:Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 2Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 3Drive Medical Equipment Chooses NacTel with ShoreTel as its Critical Communications Provider 4Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation 2
(Date:8/20/2014)... Ticketability.com has Theresa Caputo tickets for ... well-known medium has been thrilling many with her amazing ... cities, with tickets becoming available August 15. , Among ... Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, Houston, New ... Diego. The medium’s fans can obtain Theresa Caputo tour ...
(Date:8/20/2014)... 20, 2014 BuyCheapTicketsToEvents.com is always ... selection of tickets to many events. Cheap NHL hockey tickets ... in September. , Hockey fans are enthusiastic about their sport, ... for games. Now is the time to acquire 2014 NHL ... mere months. There will be a great deal of action ...
(Date:8/20/2014)... 2014 Blaine Labs®, the creators ... RevitaDERM® Psoriasis Treatment to ease the redness, ... This all-in-one product was created to treat, moisturize, ... is powered by coal tar and formulated to ... effective ingredient. , RevitaDERM® Psoriasis Treatment is ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... 2014 The “Human Insulin Market ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2019” provides ... opportunities, current market trends,and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
Breaking Medicine News(10 mins):Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4
... , IRVINE, Calif., Nov. 30 A revolutionary new ... seamless, real-time access to diagnostic images and reports with ... by Candelis, Inc., one of the fastest growing providers ... By improving workflow and doing away with the cumbersome ...
... blood-borne diseases, researchers say , MONDAY, Nov. 30 (HealthDay ... putting them at risk for blood-borne diseases, but they ... risk of infection, a new study has found. , ... centers and found that 415 -- 59 percent -- ...
... , LOS ANGELES, Nov. 30 Menopause - it,s an ... a host of uncomfortable symptoms that negatively impact quality of life. ... sweats and lethargy are just some of the life-altering symptoms of ... can show up a full ten years before actual menopause occurs ...
... ... new poll released today by Latino Decisions, the Robert Wood Johnson Foundation ... and impreMedia, shows a widespread consensus among the Latino/Hispanic electoral about the ... coverage. For the first time, health care tops the list of national ...
... , NEW YORK, Nov. 30 Of the more than ... nearly half are African American. Moreover, the HIV/AIDS infection rates in Washington, ... and Black women account for more than 90 percent of all women ... at 6:00 p.m.*, World AIDS Day, BET shines a light on these ...
... and extensive discussion in the scientific community, the Institute ... its methods for evaluating the relation between cost and ... working on certain commissions awarded by the Federal Joint ... for passing on recommendations to the GKV-Spitzenverband [National Association ...
Cached Medicine News:Health News:Candelis Announces Revolutionary Cloud-Hosted Data Services 2Health News:Candelis Announces Revolutionary Cloud-Hosted Data Services 3Health News:Med Students Often Fail to Report Needlestick Injuries 2Health News:Anti-Aging Institute of California Offers New Natural Solution for Menopause Symptoms 2Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 2Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 3Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 4Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 5Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 6Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 7Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 8Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 9Health News:BET Networks Joins the International Call to Stop the Spread of HIV on World Aids Day Tuesday, December 1 with an Annual Special Episode of '106 & PARK' and on the Ground Initiatives Through BET's Award Winning Public Affairs Campaign Rap-It-Up 2Health News:BET Networks Joins the International Call to Stop the Spread of HIV on World Aids Day Tuesday, December 1 with an Annual Special Episode of '106 & PARK' and on the Ground Initiatives Through BET's Award Winning Public Affairs Campaign Rap-It-Up 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 4Health News:IQWiG presents a method for evaluating the relation between cost and benefit 5
Stainless steel. Lamp is in fiberoptic handle. Green color coding. The blade includes a port that permits delivery of oxygen or other gas mixtures during intubation....
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Stainless steel. Lamp supplied with ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
Medicine Products: